Quture Recruits Healthcare Visionary and Accomplished Expert to Strengthen Distinguished Management Team
November 13 2012 - 7:00AM
Marketwired
Quture (OTCQB: QUTR) announced today the new hire of Paul L.
Rudisill as the company's first Chief Business Development Officer.
Rudisill is a global healthcare leader, known for his strategic and
visionary strength. With more than 30 years as a clinician and
healthcare executive, Rudisill's goal is to decrease the delta
between life's longevity and one's quality of life. Rudisill has
held leadership positions with large integrated delivery systems
(e.g. Presbyterian Healthcare System and Methodist Health Systems),
provider groups/MSOs and technology companies.
Quture is now engaged in marketing and sales of its QualOptima
Analytics and Connectivity System. Rudisill has already begun
working with his extensive contacts, dramatically adding to the
company's prospects. However, his role and responsibilities at
Quture go well beyond marketing and sales and channel distribution
to strategic planning and implementation and continued product
design, functionality and development. He is expected to play a
significant role in plans for future mergers, acquisitions and
international growth.
Rudisill's international experience and leadership is a major
factor in his selection by Quture for this position. Rudisill was
the Senior Executive for EDS' Global Healthcare Business Unit where
he was responsible for developing EDS' strategic direction by
refocusing on clinical outcomes and providing world-class service
for the health industry. Rudisill has served as a consultant to
many public and private healthcare entities both nationally and
internationally such as the New Zealand Ministry of Health, South
Australian Health Commission and other organizations in Asia/
Pacific, Latin America, Canada and the European Union. As an
example of his success, Rudisill's vision created an annual savings
of $21 million for one delivery enterprise in New Zealand, while
opening up access and quantifiably improving care.
"Despite Quture's significant first to market advantage, we find
ourselves in a continuous and competitive growing market for
healthcare analytics," said Landon Feazell, Chairman and CEO of
Quture. "Paul has previous significant involvement with the
development of Quture, and we know his immense breadth and depth of
insight, knowledge and global experience to implement the strategic
plans of Quture. His passion for transforming data to information
and information to knowledge make him an extraordinary addition to
our Management Team. His leadership in areas such as predictive
modeling and mobile phone applications will be invaluable to the
future of Quture."
After his career with EDS, Rudisill founded The Healthcare
Intellect Group (HIG) in 2000 where he focused on globalizing small
and emerging healthcare companies using his extensive relations
worldwide. HIG's clients ranged from healthcare professional
service companies to financial/clinical technology companies.
Rudisill helped to expand companies, not only in the depth of
clients, but in the extent of product offerings related to clinical
process and outcomes management. He is a hands-on executive with
extensive experience in the healthcare industry, especially in the
areas of enterprise planning/re-engineering, leadership, financial
growth, use of technologies and prospective outcomes.
"I selected Quture from many other opportunities because I am
convinced that this company, its products, strategies, and its
vision have the best opportunity to dominate the global market and
to achieve my professional goals for transforming health and health
care," said Rudisill. "With the elections over and knowing that the
Affordable Care Act will stand, the opportunities for Quture are
even greater. I firmly believe that the key to improving
healthcare, and subsequently lowering costs, is through the careful
application of technology. Improving clinical quality is about
focusing on processes and looking at how they could be improved and
streamlined. We have to be forward thinking and the only way to
have a real impact is through technology that will take us into the
future. We need to evolve from healthcare silo based processes, to
a foundation of an Outcomes Prospective Continuum with decisions
supported from Knowledge rather than retrospective Data or
Concurrent Information."
ABOUT QUTURE INTERNATIONAL, INC.
(www.quture.com) Quture International, Inc. (QUTR) is the proven and experienced performance and
outcomes analytics company in the United States. The vision of
Quture is to connect all constituents in the global health and
health care community to clinically and financially focused and
sound data transformed through analytics to knowledge that
empowers data-driven decisions for results-driven
success. As a "Breakthrough" Application Partner of
InterSystems Corporation, Quture's technology for capturing,
integrating and aggregating data on the InterSystems Enterprise
platform is unequalled. The Company's unique product QualOptima
develops a second generation CLINICAL database implementing
Quture's core competence of clinical content with evidence-based
metrics developed for more than 35 years. QualOptima empowers
clinical performance enhancement to achieve optimal patient
outcomes. Quture's brand is centered on the value proposition of
trust, transparency and independence. As the free enterprise
solution to improving health and healthcare while reducing costs,
Quture is positioned to become the leading clinical knowledge
company in the world. Quture International is a Nevada corporation
trading under the symbol QUTR.
This release contains forward-looking statements, including,
without limitation, statements concerning our business and possible
or assumed future results of operations. Our actual results could
differ materially from those anticipated in the forward-looking
statements for many reasons including: our ability to continue as a
going concern, adverse economic changes affecting markets we serve;
competition in our markets and industry segments; our timing and
the profitability of entering new markets; greater than expected
costs, customer acceptance of our products or difficulties related
to our integration of the businesses we may acquire; and other
risks and uncertainties as may be detailed from time to time in our
public announcements and SEC filings. Although we believe the
expectations reflected in the forward-looking statements are
reasonable, they relate only to events as of the date on which the
statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations. We do
not intend to update any of the forward-looking statements after
the date of this document to conform these statements to actual
results or to changes in our expectations, except as required by
law. There is no assurance that a definitive agreement will be
completed.
For Further Information Contact: Constellation Asset
Advisors, Inc. Jens Dalsgaard President +1 (415) 524-8500
Contact: Mele Telitz Director of Communications (855)
740-QUTR (7878) mele@quture.com